Veaceslav Moshin - Academia.edu (original) (raw)

Papers by Veaceslav Moshin

Human Reproduction, 2011

To explore the molecular basis of clinically observed volume reduction in uterine leomyoma, expos... more To explore the molecular basis of clinically observed volume reduction in uterine leomyoma, exposed to mifepristone. Background: Treatment of uterine leiomyomas with a selective progesterone receptor modulator (SPRM) as an alternative to surgery is of considerable clinical interest. Steroid homone receptors are overexpressed in leiomyoma tumor tissue compared to adjacent myometrium and involved in the process of leiomyoma growth. Progesterone receptor modulators such as mifepristone are effective and well tolerated in reducing myoma volume and vaginal bleeding. In a previously reported study we observed a significant volume reduction in the dominant myoma in response to mifepristone, but with a wide individual variation (median-23%, range:-81 to + 19%) in response to treatment. Thus, a study was conducted to explore the molecular basis of good response to mifepristone treatment. Material and Methods: Premenopausal women with uterine leiomyoma (n = 12) received treatment with mifepristone 50 mg every other day for 12 weeks. Among them, eight women were sub grouped as good (N = 4, median-49%, range-64 to-31%) or poor (N = 4, median-22%, range-23 to-21%) respnders. At surgery, biopsies were taken from the periphery of the dominant leiomyoma and total RNA was extracted to study the gene expression by microarray. The result was further analysed by Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com) to explore the leading molecular pathway mediating the response to mifepristone. The result from the microarray was confirmed by real time-PCR. Proliferation marker MKI67 and apoptosis marker TP53 were analysed along with apoptotic index by TUNEL assay. Ethical permission for this study was obtained prior to start of the study. Results: Twenty one canonical pathways showed significantly different expression (p < 0,05) on comparing between good and poor responders. The most differently expressed pathway was Metabolism of Xenobiotics by Cytochrome P450 pathway. The second most significant pathway and the pathway more relevant to uterine leomyoma growth is the glutathione pathway harboring glutathione-s tranferases (p = 0.0001, ratio 5%). One of the genes was downregulated (GPX2-1.7 fold) and 4 genes belonging to this family were upregulated (GSTM1 + 8.0-fold), GSTM2(+ 1.5 fold), GSTM3(+ 2.3 fold), GSTM5(+ 2.2 fold) among the good responders. Further analysis by real time PCR showed GSTM1 was not detectable in biopsies from non responders. No correlations were seen for GSTM1, MKI67 or TP53 versus percentual myoma volume reduction. TUNEL analysis showed no difference in the degree of apoptosis between good or bad responders to mifepristone. Conclusion: Our findings indicate that glutothione pathway is involved in the action of mifepristone on leiomyoma volume reduction. GSTM1 positive fenotype is of importance for uterine leiomyoma volume reduction in response to mifepristone exposure in vivo. The mechanism behind the difference in growthregulation is still not clear, but could be suggested to interfere with proliferation or repression co-regulators related to the degree of metabolism of steroids regulated by GSTMs. The finding in the present study of a tentative prognostic marker for leiomyoma volume reduction during mifepristone treatment is of potential importance for the clinical management of millions of women suffering from symptoms from uterine leiomyomas.

Human Reproduction Open, 2019

STUDY QUESTION What are the European trends and developments in ART and IUI in 2015 as compared t... more STUDY QUESTION What are the European trends and developments in ART and IUI in 2015 as compared to previous years? SUMMARY ANSWER The 19th ESHRE report on ART shows a continuing expansion of treatment numbers in Europe, and this increase, the variability in treatment modalities and the rising contribution to the birth rates in most participating countries all point towards the increasing impact of ART on European society. WHAT IS KNOWN ALREADY Since 1997, the ART data generated by national registries have been collected, analysed and reported in 18 manuscripts published in Human Reproduction. STUDY DESIGN, SIZE, DURATION Collection of European data by the European IVF-Monitoring Consortium (EIM) for ESHRE. The data for treatments performed between 1 January and 31 December 2015 in 38 European countries were provided by national registries or on a voluntary basis by clinics or professional societies. PARTICIPANTS/MATERIALS, SETTINGS, METHODS From 1343 institutions in 38 countries off...

Human Reproduction Open

STUDY QUESTION What are the data and trends on ART and IUI cycle numbers and their outcomes, and ... more STUDY QUESTION What are the data and trends on ART and IUI cycle numbers and their outcomes, and on fertility preservation (FP) interventions, reported in 2018 as compared to previous years? SUMMARY ANSWER The 22nd ESHRE report shows a continued increase in reported numbers of ART treatment cycles and children born in Europe, a decrease in transfers with more than one embryo with a further reduction of twin delivery rates (DRs) as compared to 2017, higher DRs per transfer after fresh IVF or ICSI cycles (without considering freeze-all cycles) than after frozen embryo transfer (FET) with higher pregnancy rates (PRs) after FET and the number of reported IUI cycles decreased while their PR and DR remained stable. WHAT IS KNOWN ALREADY ART aggregated data generated by national registries, clinics or professional societies have been gathered and analysed by the European IVF-monitoring Consortium (EIM) since 1997 and reported in 21 manuscripts published in Human Reproduction and Human Repr...

Human Reproduction Open, 2017

What is known in Europe about the practice of oocyte cryopreservation (OoC), in terms of current ... more What is known in Europe about the practice of oocyte cryopreservation (OoC), in terms of current statutory background, funding conditions, indications (medical and 'non-medical') and specific number of cycles? SUMMARY ANSWER: Laws and conditions for OoC vary in Europe, with just over half the responding countries providing this for medical reasons with state funding, and none providing funding for 'non-medical' OoC. WHAT IS ALREADY KNOWN: The practice of OoC is a well-established and increasing practice in some European countries, but data gathering on storage is not homogeneous, and still sparse for use. Ovarian tissue cryopreservation (OtC) is only practiced and registered in a few countries. STUDY DESIGN, SIZE, AND DURATION: A transversal collaborative survey on OoC and OtC, was designed, based on a country questionnaire containing information on statutory or professional background and practice, as well as available data on ovarian cell and tissue collection, storage and use. It was performed between January and September 2015. PARTICIPANTS/MATERIALS, SETTING AND METHODS: All ESHRE European IVF Monitoring (EIM) consortium national coordinators were contacted, as well as members of the ESHRE committee of national representatives, and sent a questionnaire. The form included national policy and practice details, whether through current existing law or code of practice, criteria for freezing (age, health status), availability of funding and the presence of a specific register. The questionnaire also included data on both the number of OoC cycles and cryopreserved oocytes per year between 2010 and 2014, specifically for egg donation, fertility preservation for medical disease, 'other medical' reasons as part of an ART cycle, as well as for 'non-medical reasons' or age-related fertility decline. Another question concerning data on freezing and use of ovarian tissue over 5 years was added and sent after receiving the initial questionnaire. MAIN RESULTS AND THE ROLE OF CHANCE: Out of 34 EIM members, we received answers regarding OoC regulations and funding conditions from 27, whilst 17 countries had recorded data for OoC, and 12 for OtC. The specific statutory framework for OoC and OtC varies from absent to a strict frame. A total of 34 705 OoC cycles were reported during the 5-year-period, with a continuous increase. However, the accurate description of numbers was concentrated on the year 2013 because it was the most complete. In 2013, a total of 9126 aspirations involving OoC were reported from 16 countries. Among the 8885 oocyte aspirations with fully available data, the majority † ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.

BACKGROUND: European results of assisted reproductive techniques from treatments initiated during... more BACKGROUND: European results of assisted reproductive techniques from treatments initiated during 2004 are presented in this eighth report. METHODS: Data were mainly collected from existing national registers. From 29 countries, 785 clinics reported 367 066 treatment cycles including: IVF (114 672), ICSI (167 192), frozen embryo replacement (FER, 71 997), egg donation (ED, 10 334), preimplantation genetic diagnosis/screening (PGD/PGS, 2701) and in vitro maturation (IVM, 170). Overall, this represents only a marginal increase since 2003, due to a huge reduction in treatments in Germany. European data on intrauterine insemination using husband/partner's semen (IUI-H) and donor semen (IUI-D) were reported from 20 countries. A total of 115 980 cycles (IUI-H, 98 388; IUI-D, 17 592) were included. RESULTS: In 14 countries where all clinics reported to the IVF register, a total of 248 937 ART cycles were performed in a population of 261.6 million, corresponding to 1095 cycles per million inhabitants. For IVF, the clinical pregnancy rates per aspiration and per transfer were 26.6% and 30.1%, respectively. For ICSI, the corresponding rates were 27.1% and 29.8%. After IUI-H, the clinical pregnancy rate was 12.6% in women below 40. After IVF and ICSI, the distribution of transfer of 1, 2, 3 and 4 or more embryos was 19.2%, 55.3%, 22.1% and 3.3%, respectively. Compared with 2003, fewer embryos were transferred, but huge differences still existed between countries. The distribution of singleton, twin and triplet deliveries after IVF and ICSI combined was 77.2%, 21.7% and 1.0%, respectively. This gives a total multiple delivery rate of 22.7% compared with 23.1% in 2003 and 24.5% in 2002. After IUI-H in women below 40 years of age, 11.9% were twin and 1.3% triplet gestations. CONCLUSIONS: Compared with earlier years, the reported number of ART cycles in Europe increased and the pregnancy rates increased marginally, even though fewer embryos were transferred and the multiple delivery rates were reduced.

Human Reproduction, 2017

STUDY QUESTION Are there any changes in the treatments involving ART and IUI initiated in Europe ... more STUDY QUESTION Are there any changes in the treatments involving ART and IUI initiated in Europe during 2013 compared with previous years? SUMMARY ANSWER An increase in the overall number of ART cycles resulting from a higher number of countries reporting data was evident, the pregnancy rates (PRs) in 2013 remained stable compared with those reported in 2012, the number of transfers with multiple embryos (3+) was lower than ever before yet the multiple delivery rates (DRs) remained unchanged, and IUI activity and success rates were similar to those of last years. WHAT IS KNOWN ALREADY Since 1997, ART data in Europe have been collected and reported in 16 manuscripts, published in Human Reproduction. STUDY DESIGN, SIZE, DURATION Retrospective data collection of European ART data by the European IVF-monitoring Consortium for ESHRE. Data for cycles between 1 January and 31 December 2013 were collected from National Registers, when existing, or on a voluntary basis by personal informatio...

Human Reproduction Open

STUDY QUESTION What are the data on ART and IUI cycles, and fertility preservation (FP) intervent... more STUDY QUESTION What are the data on ART and IUI cycles, and fertility preservation (FP) interventions reported in 2017 as compared to previous years, as well as the main trends over the years? SUMMARY ANSWER The 21st ESHRE report on ART and IUI shows the continual increase in reported treatment cycle numbers in Europe, with a decrease in the proportion of transfers with more than one embryo causing an additional slight reduction of multiple delivery rates (DR) as well as higher pregnancy rates (PR) and DR after frozen embryo replacement (FER) compared to fresh IVF and ICSI cycles, while the number of IUI cycles increased and their outcomes remained stable. WHAT IS KNOWN ALREADY Since 1997, ART aggregated data generated by national registries, clinics or professional societies have been gathered and analyzed by the European IVF-monitoring Consortium (EIM) and communicated in a total of 20 manuscripts published in Human Reproduction and Human Reproduction Open. STUDY DESIGN, SIZE, DUR...

International Journal of Gynecology & Obstetrics, 2009

pamphlet and informed that a free pap smear test be formed. The data of this research was gathere... more pamphlet and informed that a free pap smear test be formed. The data of this research was gathered by a guestionnaire in two stages, before and 2 month after education, and then by SPSS software by using descriptive statistics and analytical statistics such as Wilcoxon and McNemar and Fisher were analyzed. Results: The results of this study indicated that there was significant difference in perceived susceptibility (p < 0.001), perceived severity (p < 0.001), perceived benefits (p < 0.001) and barrier (p < 0.001) before and after education. Conclusion: Finding of this study showed that education through health belief model was effective in pereventing cervival cancer. Then this educational model can be applied in educating other women for preventing cervical cancer.

Human Reproduction

The 18th ESHRE report on ART shows a continuing expansion of both treatment numbers in Europe and... more The 18th ESHRE report on ART shows a continuing expansion of both treatment numbers in Europe and more variability in treatment modalities resulting in a rising contribution to the birth rates in most participating countries. WHAT IS KNOWN ALREADY: Since 1997, ART data generated by national registries have been collected, analysed by the European IVF-monitoring (EIM) Consortium and reported in 17 manuscripts published in Human Reproduction. STUDY DESIGN, SIZE, DURATION: Continuous collection of European data by the EIM for ESHRE. The data for treatments performed in 2014 between 1 January and 31 December in 39 European countries were provided by national registries or on a voluntary basis by clinics or professional societies.

Human Reproduction Open

STUDY QUESTION What are the reported data on cycles in ART, IUI and fertility preservation (FP) i... more STUDY QUESTION What are the reported data on cycles in ART, IUI and fertility preservation (FP) interventions in 2016 as compared to previous years, as well as the main trends over the years? SUMMARY ANSWER The 20th ESHRE report on ART and IUI shows a progressive increase in reported treatment cycle numbers in Europe, with a decrease in the number of transfers with more than one embryo causing a reduction of multiple delivery rates (DR), as well as higher pregnancy rates and DR after frozen embryo replacement (FER) compared to fresh IVF and ICSI cycles, while the outcomes for IUI cycles remained stable. WHAT IS KNOWN ALREADY Since 1997, ART aggregated data generated by national registries, clinics or professional societies have been collected, analysed by the European IVF-monitoring Consortium (EIM) and reported in 19 manuscripts published in Human Reproduction and Human Reproduction Open. STUDY DESIGN, SIZE, DURATION Yearly collection of European medically assisted reproduction (MA...

Human Reproduction, 2011

To explore the molecular basis of clinically observed volume reduction in uterine leomyoma, expos... more To explore the molecular basis of clinically observed volume reduction in uterine leomyoma, exposed to mifepristone. Background: Treatment of uterine leiomyomas with a selective progesterone receptor modulator (SPRM) as an alternative to surgery is of considerable clinical interest. Steroid homone receptors are overexpressed in leiomyoma tumor tissue compared to adjacent myometrium and involved in the process of leiomyoma growth. Progesterone receptor modulators such as mifepristone are effective and well tolerated in reducing myoma volume and vaginal bleeding. In a previously reported study we observed a significant volume reduction in the dominant myoma in response to mifepristone, but with a wide individual variation (median-23%, range:-81 to + 19%) in response to treatment. Thus, a study was conducted to explore the molecular basis of good response to mifepristone treatment. Material and Methods: Premenopausal women with uterine leiomyoma (n = 12) received treatment with mifepristone 50 mg every other day for 12 weeks. Among them, eight women were sub grouped as good (N = 4, median-49%, range-64 to-31%) or poor (N = 4, median-22%, range-23 to-21%) respnders. At surgery, biopsies were taken from the periphery of the dominant leiomyoma and total RNA was extracted to study the gene expression by microarray. The result was further analysed by Ingenuity Pathway Analysis (IPA, Ingenuity® Systems, www.ingenuity.com) to explore the leading molecular pathway mediating the response to mifepristone. The result from the microarray was confirmed by real time-PCR. Proliferation marker MKI67 and apoptosis marker TP53 were analysed along with apoptotic index by TUNEL assay. Ethical permission for this study was obtained prior to start of the study. Results: Twenty one canonical pathways showed significantly different expression (p < 0,05) on comparing between good and poor responders. The most differently expressed pathway was Metabolism of Xenobiotics by Cytochrome P450 pathway. The second most significant pathway and the pathway more relevant to uterine leomyoma growth is the glutathione pathway harboring glutathione-s tranferases (p = 0.0001, ratio 5%). One of the genes was downregulated (GPX2-1.7 fold) and 4 genes belonging to this family were upregulated (GSTM1 + 8.0-fold), GSTM2(+ 1.5 fold), GSTM3(+ 2.3 fold), GSTM5(+ 2.2 fold) among the good responders. Further analysis by real time PCR showed GSTM1 was not detectable in biopsies from non responders. No correlations were seen for GSTM1, MKI67 or TP53 versus percentual myoma volume reduction. TUNEL analysis showed no difference in the degree of apoptosis between good or bad responders to mifepristone. Conclusion: Our findings indicate that glutothione pathway is involved in the action of mifepristone on leiomyoma volume reduction. GSTM1 positive fenotype is of importance for uterine leiomyoma volume reduction in response to mifepristone exposure in vivo. The mechanism behind the difference in growthregulation is still not clear, but could be suggested to interfere with proliferation or repression co-regulators related to the degree of metabolism of steroids regulated by GSTMs. The finding in the present study of a tentative prognostic marker for leiomyoma volume reduction during mifepristone treatment is of potential importance for the clinical management of millions of women suffering from symptoms from uterine leiomyomas.

Human Reproduction Open, 2019

STUDY QUESTION What are the European trends and developments in ART and IUI in 2015 as compared t... more STUDY QUESTION What are the European trends and developments in ART and IUI in 2015 as compared to previous years? SUMMARY ANSWER The 19th ESHRE report on ART shows a continuing expansion of treatment numbers in Europe, and this increase, the variability in treatment modalities and the rising contribution to the birth rates in most participating countries all point towards the increasing impact of ART on European society. WHAT IS KNOWN ALREADY Since 1997, the ART data generated by national registries have been collected, analysed and reported in 18 manuscripts published in Human Reproduction. STUDY DESIGN, SIZE, DURATION Collection of European data by the European IVF-Monitoring Consortium (EIM) for ESHRE. The data for treatments performed between 1 January and 31 December 2015 in 38 European countries were provided by national registries or on a voluntary basis by clinics or professional societies. PARTICIPANTS/MATERIALS, SETTINGS, METHODS From 1343 institutions in 38 countries off...

Human Reproduction Open

STUDY QUESTION What are the data and trends on ART and IUI cycle numbers and their outcomes, and ... more STUDY QUESTION What are the data and trends on ART and IUI cycle numbers and their outcomes, and on fertility preservation (FP) interventions, reported in 2018 as compared to previous years? SUMMARY ANSWER The 22nd ESHRE report shows a continued increase in reported numbers of ART treatment cycles and children born in Europe, a decrease in transfers with more than one embryo with a further reduction of twin delivery rates (DRs) as compared to 2017, higher DRs per transfer after fresh IVF or ICSI cycles (without considering freeze-all cycles) than after frozen embryo transfer (FET) with higher pregnancy rates (PRs) after FET and the number of reported IUI cycles decreased while their PR and DR remained stable. WHAT IS KNOWN ALREADY ART aggregated data generated by national registries, clinics or professional societies have been gathered and analysed by the European IVF-monitoring Consortium (EIM) since 1997 and reported in 21 manuscripts published in Human Reproduction and Human Repr...

Human Reproduction Open, 2017

What is known in Europe about the practice of oocyte cryopreservation (OoC), in terms of current ... more What is known in Europe about the practice of oocyte cryopreservation (OoC), in terms of current statutory background, funding conditions, indications (medical and 'non-medical') and specific number of cycles? SUMMARY ANSWER: Laws and conditions for OoC vary in Europe, with just over half the responding countries providing this for medical reasons with state funding, and none providing funding for 'non-medical' OoC. WHAT IS ALREADY KNOWN: The practice of OoC is a well-established and increasing practice in some European countries, but data gathering on storage is not homogeneous, and still sparse for use. Ovarian tissue cryopreservation (OtC) is only practiced and registered in a few countries. STUDY DESIGN, SIZE, AND DURATION: A transversal collaborative survey on OoC and OtC, was designed, based on a country questionnaire containing information on statutory or professional background and practice, as well as available data on ovarian cell and tissue collection, storage and use. It was performed between January and September 2015. PARTICIPANTS/MATERIALS, SETTING AND METHODS: All ESHRE European IVF Monitoring (EIM) consortium national coordinators were contacted, as well as members of the ESHRE committee of national representatives, and sent a questionnaire. The form included national policy and practice details, whether through current existing law or code of practice, criteria for freezing (age, health status), availability of funding and the presence of a specific register. The questionnaire also included data on both the number of OoC cycles and cryopreserved oocytes per year between 2010 and 2014, specifically for egg donation, fertility preservation for medical disease, 'other medical' reasons as part of an ART cycle, as well as for 'non-medical reasons' or age-related fertility decline. Another question concerning data on freezing and use of ovarian tissue over 5 years was added and sent after receiving the initial questionnaire. MAIN RESULTS AND THE ROLE OF CHANCE: Out of 34 EIM members, we received answers regarding OoC regulations and funding conditions from 27, whilst 17 countries had recorded data for OoC, and 12 for OtC. The specific statutory framework for OoC and OtC varies from absent to a strict frame. A total of 34 705 OoC cycles were reported during the 5-year-period, with a continuous increase. However, the accurate description of numbers was concentrated on the year 2013 because it was the most complete. In 2013, a total of 9126 aspirations involving OoC were reported from 16 countries. Among the 8885 oocyte aspirations with fully available data, the majority † ESHRE Pages content is not externally peer reviewed. The manuscript has been approved by the Executive Committee of ESHRE.

BACKGROUND: European results of assisted reproductive techniques from treatments initiated during... more BACKGROUND: European results of assisted reproductive techniques from treatments initiated during 2004 are presented in this eighth report. METHODS: Data were mainly collected from existing national registers. From 29 countries, 785 clinics reported 367 066 treatment cycles including: IVF (114 672), ICSI (167 192), frozen embryo replacement (FER, 71 997), egg donation (ED, 10 334), preimplantation genetic diagnosis/screening (PGD/PGS, 2701) and in vitro maturation (IVM, 170). Overall, this represents only a marginal increase since 2003, due to a huge reduction in treatments in Germany. European data on intrauterine insemination using husband/partner's semen (IUI-H) and donor semen (IUI-D) were reported from 20 countries. A total of 115 980 cycles (IUI-H, 98 388; IUI-D, 17 592) were included. RESULTS: In 14 countries where all clinics reported to the IVF register, a total of 248 937 ART cycles were performed in a population of 261.6 million, corresponding to 1095 cycles per million inhabitants. For IVF, the clinical pregnancy rates per aspiration and per transfer were 26.6% and 30.1%, respectively. For ICSI, the corresponding rates were 27.1% and 29.8%. After IUI-H, the clinical pregnancy rate was 12.6% in women below 40. After IVF and ICSI, the distribution of transfer of 1, 2, 3 and 4 or more embryos was 19.2%, 55.3%, 22.1% and 3.3%, respectively. Compared with 2003, fewer embryos were transferred, but huge differences still existed between countries. The distribution of singleton, twin and triplet deliveries after IVF and ICSI combined was 77.2%, 21.7% and 1.0%, respectively. This gives a total multiple delivery rate of 22.7% compared with 23.1% in 2003 and 24.5% in 2002. After IUI-H in women below 40 years of age, 11.9% were twin and 1.3% triplet gestations. CONCLUSIONS: Compared with earlier years, the reported number of ART cycles in Europe increased and the pregnancy rates increased marginally, even though fewer embryos were transferred and the multiple delivery rates were reduced.

Human Reproduction, 2017

STUDY QUESTION Are there any changes in the treatments involving ART and IUI initiated in Europe ... more STUDY QUESTION Are there any changes in the treatments involving ART and IUI initiated in Europe during 2013 compared with previous years? SUMMARY ANSWER An increase in the overall number of ART cycles resulting from a higher number of countries reporting data was evident, the pregnancy rates (PRs) in 2013 remained stable compared with those reported in 2012, the number of transfers with multiple embryos (3+) was lower than ever before yet the multiple delivery rates (DRs) remained unchanged, and IUI activity and success rates were similar to those of last years. WHAT IS KNOWN ALREADY Since 1997, ART data in Europe have been collected and reported in 16 manuscripts, published in Human Reproduction. STUDY DESIGN, SIZE, DURATION Retrospective data collection of European ART data by the European IVF-monitoring Consortium for ESHRE. Data for cycles between 1 January and 31 December 2013 were collected from National Registers, when existing, or on a voluntary basis by personal informatio...

Human Reproduction Open

STUDY QUESTION What are the data on ART and IUI cycles, and fertility preservation (FP) intervent... more STUDY QUESTION What are the data on ART and IUI cycles, and fertility preservation (FP) interventions reported in 2017 as compared to previous years, as well as the main trends over the years? SUMMARY ANSWER The 21st ESHRE report on ART and IUI shows the continual increase in reported treatment cycle numbers in Europe, with a decrease in the proportion of transfers with more than one embryo causing an additional slight reduction of multiple delivery rates (DR) as well as higher pregnancy rates (PR) and DR after frozen embryo replacement (FER) compared to fresh IVF and ICSI cycles, while the number of IUI cycles increased and their outcomes remained stable. WHAT IS KNOWN ALREADY Since 1997, ART aggregated data generated by national registries, clinics or professional societies have been gathered and analyzed by the European IVF-monitoring Consortium (EIM) and communicated in a total of 20 manuscripts published in Human Reproduction and Human Reproduction Open. STUDY DESIGN, SIZE, DUR...

International Journal of Gynecology & Obstetrics, 2009

pamphlet and informed that a free pap smear test be formed. The data of this research was gathere... more pamphlet and informed that a free pap smear test be formed. The data of this research was gathered by a guestionnaire in two stages, before and 2 month after education, and then by SPSS software by using descriptive statistics and analytical statistics such as Wilcoxon and McNemar and Fisher were analyzed. Results: The results of this study indicated that there was significant difference in perceived susceptibility (p < 0.001), perceived severity (p < 0.001), perceived benefits (p < 0.001) and barrier (p < 0.001) before and after education. Conclusion: Finding of this study showed that education through health belief model was effective in pereventing cervival cancer. Then this educational model can be applied in educating other women for preventing cervical cancer.

Human Reproduction

The 18th ESHRE report on ART shows a continuing expansion of both treatment numbers in Europe and... more The 18th ESHRE report on ART shows a continuing expansion of both treatment numbers in Europe and more variability in treatment modalities resulting in a rising contribution to the birth rates in most participating countries. WHAT IS KNOWN ALREADY: Since 1997, ART data generated by national registries have been collected, analysed by the European IVF-monitoring (EIM) Consortium and reported in 17 manuscripts published in Human Reproduction. STUDY DESIGN, SIZE, DURATION: Continuous collection of European data by the EIM for ESHRE. The data for treatments performed in 2014 between 1 January and 31 December in 39 European countries were provided by national registries or on a voluntary basis by clinics or professional societies.

Human Reproduction Open

STUDY QUESTION What are the reported data on cycles in ART, IUI and fertility preservation (FP) i... more STUDY QUESTION What are the reported data on cycles in ART, IUI and fertility preservation (FP) interventions in 2016 as compared to previous years, as well as the main trends over the years? SUMMARY ANSWER The 20th ESHRE report on ART and IUI shows a progressive increase in reported treatment cycle numbers in Europe, with a decrease in the number of transfers with more than one embryo causing a reduction of multiple delivery rates (DR), as well as higher pregnancy rates and DR after frozen embryo replacement (FER) compared to fresh IVF and ICSI cycles, while the outcomes for IUI cycles remained stable. WHAT IS KNOWN ALREADY Since 1997, ART aggregated data generated by national registries, clinics or professional societies have been collected, analysed by the European IVF-monitoring Consortium (EIM) and reported in 19 manuscripts published in Human Reproduction and Human Reproduction Open. STUDY DESIGN, SIZE, DURATION Yearly collection of European medically assisted reproduction (MA...